vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and ServisFirst Bancshares, Inc. (SFBS). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $159.0M, roughly 1.6× ServisFirst Bancshares, Inc.). ServisFirst Bancshares, Inc. runs the higher net margin — 52.2% vs 11.1%, a 41.1% gap on every dollar of revenue. Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 17.7%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
ServisFirst Bancshares, Inc. is a U.S.-based bank holding company operating full-service banking locations primarily across the Southeastern United States. It offers a full suite of commercial banking, consumer banking, wealth management, and mortgage lending services to small and medium-sized businesses, professional clients, and individual consumers.
ANIP vs SFBS — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $159.0M |
| Net Profit | $27.5M | $83.0M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | — |
| Net Margin | 11.1% | 52.2% |
| Revenue YoY | 29.6% | — |
| Net Profit YoY | 367.5% | 31.2% |
| EPS (diluted) | $1.14 | $1.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $159.0M | ||
| Q4 25 | $247.1M | $162.2M | ||
| Q3 25 | $227.8M | $136.3M | ||
| Q2 25 | $211.4M | $132.1M | ||
| Q1 25 | $197.1M | $131.8M | ||
| Q4 24 | $190.6M | $131.9M | ||
| Q3 24 | $148.3M | $123.7M | ||
| Q2 24 | $138.0M | $114.8M |
| Q1 26 | — | $83.0M | ||
| Q4 25 | $27.5M | $86.4M | ||
| Q3 25 | $26.6M | $65.6M | ||
| Q2 25 | $8.5M | $61.4M | ||
| Q1 25 | $15.7M | $63.2M | ||
| Q4 24 | $-10.3M | $65.2M | ||
| Q3 24 | $-24.2M | $59.9M | ||
| Q2 24 | $-2.3M | $52.1M |
| Q1 26 | — | — | ||
| Q4 25 | 14.1% | 66.3% | ||
| Q3 25 | 15.9% | 57.8% | ||
| Q2 25 | 6.6% | 58.0% | ||
| Q1 25 | 13.3% | 60.0% | ||
| Q4 24 | -2.3% | 60.2% | ||
| Q3 24 | -13.8% | 58.5% | ||
| Q2 24 | 3.7% | 58.0% |
| Q1 26 | — | 52.2% | ||
| Q4 25 | 11.1% | 59.0% | ||
| Q3 25 | 11.7% | 48.1% | ||
| Q2 25 | 4.0% | 46.5% | ||
| Q1 25 | 8.0% | 48.0% | ||
| Q4 24 | -5.4% | 52.9% | ||
| Q3 24 | -16.3% | 48.4% | ||
| Q2 24 | -1.7% | 45.4% |
| Q1 26 | — | $1.52 | ||
| Q4 25 | $1.14 | $1.58 | ||
| Q3 25 | $1.13 | $1.20 | ||
| Q2 25 | $0.36 | $1.12 | ||
| Q1 25 | $0.69 | $1.16 | ||
| Q4 24 | $-0.45 | $1.19 | ||
| Q3 24 | $-1.27 | $1.10 | ||
| Q2 24 | $-0.14 | $0.95 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $1.8B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $1.9B |
| Total Assets | $1.4B | $18.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.8B | ||
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | — | ||
| Q2 25 | $217.8M | — | ||
| Q1 25 | $149.8M | — | ||
| Q4 24 | $144.9M | — | ||
| Q3 24 | $145.0M | — | ||
| Q2 24 | $240.1M | — |
| Q1 26 | — | $1.9B | ||
| Q4 25 | $540.7M | $1.8B | ||
| Q3 25 | $505.8M | $1.8B | ||
| Q2 25 | $436.8M | $1.7B | ||
| Q1 25 | $418.6M | $1.7B | ||
| Q4 24 | $403.7M | $1.6B | ||
| Q3 24 | $405.9M | $1.6B | ||
| Q2 24 | $455.8M | $1.5B |
| Q1 26 | — | $18.2B | ||
| Q4 25 | $1.4B | $17.7B | ||
| Q3 25 | $1.4B | $17.6B | ||
| Q2 25 | $1.3B | $17.4B | ||
| Q1 25 | $1.3B | $18.6B | ||
| Q4 24 | $1.3B | $17.4B | ||
| Q3 24 | $1.3B | $16.4B | ||
| Q2 24 | $920.8M | $16.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | — |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $355.2M | ||
| Q3 25 | $44.1M | $140.9M | ||
| Q2 25 | $75.8M | $67.6M | ||
| Q1 25 | $35.0M | $48.0M | ||
| Q4 24 | $15.9M | $252.9M | ||
| Q3 24 | $12.5M | $84.0M | ||
| Q2 24 | $17.4M | $48.3M |
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $71.8M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $13.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | 34.0% | — | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 9.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 3.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 4.11× | ||
| Q3 25 | 1.66× | 2.15× | ||
| Q2 25 | 8.87× | 1.10× | ||
| Q1 25 | 2.23× | 0.76× | ||
| Q4 24 | — | 3.88× | ||
| Q3 24 | — | 1.40× | ||
| Q2 24 | — | 0.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
SFBS
| Net Interest Income | $148.1M | 93% |
| Noninterest Income | $10.8M | 7% |
